Difference between revisions of "Cooper TM, et al. Pediatr. Blood Cancer (2017) cited as Ref 631 in DOI: 10.1038/s41392-020-0110-5 (Q9894)"
Jump to navigation
Jump to search
(Created a new Item: #quickstatements; #temporary_batch_1589975872009) |
(Created claim: title (P93): A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: a Pediatric O...) |
||||||||||||||
| (5 intermediate revisions by the same user not shown) | |||||||||||||||
| Property / First Author string | |||||||||||||||
| + | Cooper TM | ||||||||||||||
| Property / First Author string: Cooper TM / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Publication Date | |||||||||||||||
| + | 2017
| ||||||||||||||
| Property / Publication Date: 2017 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Published In Name String | |||||||||||||||
| + | Pediatr. Blood Cancer | ||||||||||||||
| Property / Published In Name String: Pediatr. Blood Cancer / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Volume | |||||||||||||||
| + | 64 | ||||||||||||||
| Property / Volume: 64 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / title | |||||||||||||||
| + | A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: a Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03). (English) | ||||||||||||||
| Property / title: A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: a Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03). (English) / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| links / sliswiki / name | links / sliswiki / name | ||||||||||||||
| + | |||||||||||||||
Latest revision as of 22:05, 20 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Cooper TM, et al. Pediatr. Blood Cancer (2017) cited as Ref 631 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Cooper TM
0 references
2017
0 references
Pediatr. Blood Cancer
0 references
64
0 references
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: a Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03). (English)
0 references
